- Update to our [FDA-Approved Oncology Therapies](https://www.oncokb.org/oncology-therapies) page
- Updated Therapeutic Implications - Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)

| Level | Gene  | Mutation                                                                                                                                                                                                                                                            | Cancer Type                | Level-Associated Drug(s) in OncoKB™                                                                                                                                              | Drug(s) Added to OncoKB™                   | Evidence                                                                                                                                                                                                                                                |
| :---- | :---- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | :----------------------------------------- | :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| 1     | ERBB2 | Tyrosine Kinase Domain Activating Mutations (V697L, Q709L, A710V, E717D, L726F, L726I, T733I, L768S, L755A, L755P, L755S, L755W, I767M, D769H, D769Y, V773L, G776S, G776V, V777L, V777M, V794M, T798M, D808N, G815R, D821N, L841V, V842I, L866M, L869R, 770_831ins) | Non-Small Cell Lung Cancer | Trastuzumab Deruxtecan (Level 1\)<br/><br/>Ado-Trastuzumab Emtansine (Level 2\)<br/><br/>Neratinib, Sevabertinib, Trastuzumab \+ Pertuzumab \+ Docetaxel, Zongertinib (Level 3A) | Zongertinib (Level 1, previously Level 3A) | [FDA approval of zongertinib](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations); PMID: [40293180](https://pubmed.ncbi.nlm.nih.gov/40293180/) |

####

- Addition of 4 new genes:
  - A1CF
  - ADAR
  - L1TD1
  - RELA
